In a move reflecting a sharp strategic shift following the pandemic era, German biotech firm BioNTech has confirmed it will shut down its manufacturing site and regional headquarters in Singapore by the end of February 2027.
Context and Drivers of the Decision
The facility, located in the Tuas Biomedical Park, was acquired by BioNTech from Novartis in November 2022. At that time, BioNTech was at its commercial peak, recording 17.3 billion euros in sales driven by the success of the Comirnaty COVID-19 vaccine. However, the current landscape has shifted:
-
Sharp Revenue Decline: The company’s total sales for 2025 fell to 2.9 billion euros (approx. $3.3 billion), mirroring a broader industry trend of dwindling vaccine demand also felt by competitors like Pfizer and Moderna.
-
Cost Optimization: BioNTech stated the closure follows a comprehensive review to “align capacity with our clinical portfolio and long-term strategic direction.” The firm is prioritizing operational efficiency and sustainable value creation.
Impact and Transition Plans
The cessation of operations in Singapore affects both infrastructure and the workforce:
-
Workforce: Approximately 85 employees currently at the site will be offered severance packages and outplacement support.
-
Canceled Capacity: Originally intended to be operational by late 2023, the plant was projected to produce several hundred million mRNA vaccine doses annually.
An Uncertain Future for the mRNA Specialist
This decision comes as BioNTech navigates significant leadership changes and a pivot in its core mission:
-
Leadership Transition: In March, co-founders CEO Uğur Şahin and CMO Özlem Türeci announced they would depart the company by year-end to launch a new venture focused on “next-generation mRNA innovations.”
-
Pivot to Oncology: BioNTech is striving to evolve beyond its COVID-19 roots into a “fully integrated immunotherapy powerhouse.” The company is currently funneling investments into multiple late-stage oncology programs to secure its future growth.